Trials / Recruiting
RecruitingNCT06044662
Prognostic Value of Biomarkers in Polyneuropathy.
The Prognostic Value of Blood Biomarkers for Patients With Polyneuropathy.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Rigshospitalet, Denmark · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Biomarkers for prognosis of patients with polyneuropathy.
Detailed description
AIM: To investigate biomarkers' use as a prognostic tool in polyneuropathy patients. STUDY DESIGN: Prospective cohort study of patients with polyneuropathy. METHODS: 200 patients with polyneuropathy will be examined with physical tests, medical examination, questionnaires, and blood biomarkers at baseline and at 1-year follow-up, and 2-year follow-up. ANALYSIS: The investigators will calculate the odds of disease progression after 2 years depending on biomarkers levels at baseline using multiple logistic regression with sex and age adjustment. Diagnostic performance of the physical tests and biomarkers for prediction of disease progression will be assessed by Receiver Operating Characteristic Curve analysis with the area under the curve.
Conditions
Timeline
- Start date
- 2023-10-27
- Primary completion
- 2025-10-01
- Completion
- 2026-10-01
- First posted
- 2023-09-21
- Last updated
- 2024-04-11
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT06044662. Inclusion in this directory is not an endorsement.